Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is set to announce its earnings results on Friday, March 29th.
Eloxx Pharmaceuticals Price Performance
Eloxx Pharmaceuticals stock opened at $0.90 on Thursday. Eloxx Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $10.90. The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.71. The stock has a market capitalization of $2.83 million, a PE ratio of -0.10 and a beta of 2.73.
Institutional Investors Weigh In On Eloxx Pharmaceuticals
A hedge fund recently bought a new stake in Eloxx Pharmaceuticals stock. Renaissance Technologies LLC acquired a new position in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 179,400 shares of the company’s stock, valued at approximately $48,000. Renaissance Technologies LLC owned 0.21% of Eloxx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 2.90% of the company’s stock.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
Further Reading
- Five stocks we like better than Eloxx Pharmaceuticals
- 10 Best Airline Stocks to Buy
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What is Put Option Volume?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- How to invest in marijuana stocks in 7 stepsĀ
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.